Products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC21981	CD73 inhibitor AB-680 Featured	AB680 (AB-680) is a highly potent, selective, reversible inhibitor of CD73 with Ki/IC50 of 4.9/70 pM (hCD73), displays > 10,000-fold selectivity against related ecto-nucleotidases (CD39, NTPDases 2/3/8) and a large panel of unrelated enzymes, receptors, a
DC9029	Abacavir	Abacavir is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.
DC8161	Xeglyze(Abametapir) Featured	Abametapir is the active ingredient of Xeglyze Lotion.
DC11452	ABBV-744 Featured	ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.
DC11299	ABC 1183 Featured	ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu
DC5027	ABC294640（Opaganib） Featured	ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.
DC10929	ABC99	ABC99 is a potent, selective inhibitor of the Wnt-deacylating enzyme serine hydrolase NOTUM with IC50 of 13 nM, shows excellent selectivity across the serine hydrolase family.
DC12444	ABD-1970	ABD-1970 (ABD1970) is a highly potent, selective Monoacylglycerol lipase (MGLL) inhibitor with IC50 of 13 nM (human MGLL).
DC11925	ABD328	ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo.
DC20620	ABD345	ABD345 is a small molecule inhibitor of RANKL signalling, inhibits TNF-induced NF-κB and MAPK activation and inflammation.
DC23586	Abeprazan	Abeprazan is an acid pump inhibitor..
DC2710	Abiraterone (CB-7598)	Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM.
DC24211	Abiraterone (D4A) Featured	Abiraterone (D4A) is an active metabolite of the CYP17A1 inhibitor abiraterone.
DC20619	ABL127 Featured	ABL127 (ML174) is a potent, selective, covalent inhibitor of protein methylesterase 1 (PME-1) with IC50 of 10 nM.
DC20298	ABL-IN-29	ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively..
DC20299	ABMA	ABMA is a novel broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite.
DC8667	AB-MECA Featured	AB-MECA is a high affinity A3 adenosine receptor agonist, has high affinity for recombinant A1 and A3 receptors.
DC21983	Abn-CBD	Abn-CBD (Abnormal Cannabidiol) is a selective agonist of GPR55 receptor with EC50 of 2.5 uM, shows no significant activity against CB1 and CB2 receptors (EC50>30 uM).
DC11762	ABP-A3	ABP-A3(ABP A3) is an inhibitor of ubiquitin conjugation that targets ubiquitin and Nedd8 E1 enzymes.
DC20625	ABT-072	ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b).
DC22258	ABT-080	ABT-080 is a potent FLAP inhibitor that inhibits ionophore-stimulated LTB(4) formation with with IC50 of 20 nM.
DC20626	ABT-089	ABT-089 (Pozanicline) is a potent, selective α4β2 nAChR agonist with Ki of 16 nM.
DC21984	ABT-100	ABT-100 (ABT100) is a highly selective, potent, orally bioavailable inhibitor of farnesyltransferase (FTase).
DC20628	ABT-102	ABT-102 is a potent, highly selective, orally active TRPV1 antagonist that inhibits agonist-evoked increases in intracellular Ca(2+) levels with IC50 of 5-7 nM.
DC20629	ABT-107	ABT-107 is a potent and selective α7 nAChR agonist with Ki of 0.2-0.6 nM for rat or human cortex α7 nAChRs.
DC2002	Venetoclax(ABT-199) Featured	Venetoclax (ABT-199; GDC-0199) is a highly selective, orally bioavailable small-molecule inhibitor of Bcl-2, exhibiting sub-nanomolar binding affinity with a Ki of less than 0.01 nM. This compound has been demonstrated to induce autophagy, highlighting its role in modulating programmed cell death pathways. In vitro studies reveal that Venetoclax exhibits potent cytotoxic activity against FL5.12-BCL-2 cells, with an EC50 of 4 nM, while showing markedly reduced efficacy against FL5.12-BCL-XL cells (EC50 = 261 nM), underscoring its selectivity for Bcl-2 over Bcl-XL. The selectivity of Venetoclax is further corroborated in cellular mammalian two-hybrid assays, where it effectively disrupts BCL-2-BIM protein-protein interactions with an EC50 of 3 nM. In contrast, it demonstrates significantly weaker activity against BCL-XL-BCL-XS and MCL-1-NOXA complexes, with EC50 values of 2.2 μM, reinforcing its specificity for Bcl-2-dependent apoptotic regulation. In vivo efficacy studies utilizing xenograft models derived from RS4;11 cells, a representative model of acute lymphoblastic leukemia (ALL), demonstrate that a single oral dose of Venetoclax (12.5 mg/kg) achieves a maximal tumor growth inhibition (TGImax) of 47% (P < 0.001) and a tumor growth delay (TGD) of 26% (P < 0.05). These results indicate robust anti-tumor activity in a Bcl-2-dependent malignancy.
DC4127	ABT-263 (Navitoclax) Featured	ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.
DC23537	ABT-288	ABT-288 is a potent, selective and competitive antagonist of H3 receptor with Ki of 1.9/8.2 nM for human/rat H3 respectively.
DC7352	ABT-333 Featured	ABT-333 is an NS5B non-nucleoside polymerase inhibitor.
DC10049	Tebanicline(ABT-594) Featured	ABT-594 represents a novel class of broad-spectrum analgesics whose primary mechanism of action is activation of the neuronal nicotinic acetylcholine receptors.

<Prev1...97 98 99 100 101...1430 Next>

Products

Customized Consultation X

Your information is safe with us. * Required Fields.